Cetera Investment Advisers Acquires 3,688 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Cetera Investment Advisers lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 45.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,857 shares of the company’s stock after purchasing an additional 3,688 shares during the quarter. Cetera Investment Advisers’ holdings in Neurocrine Biosciences were worth $1,311,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC increased its position in shares of Neurocrine Biosciences by 2.1% during the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company’s stock valued at $575,000 after buying an additional 87 shares during the period. Utah Retirement Systems grew its position in Neurocrine Biosciences by 0.6% during the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company’s stock valued at $2,264,000 after acquiring an additional 100 shares during the last quarter. GeoWealth Management LLC grew its position in Neurocrine Biosciences by 65.4% during the fourth quarter. GeoWealth Management LLC now owns 258 shares of the company’s stock valued at $35,000 after acquiring an additional 102 shares during the last quarter. Aurora Investment Counsel grew its position in Neurocrine Biosciences by 1.3% during the first quarter. Aurora Investment Counsel now owns 10,520 shares of the company’s stock valued at $1,164,000 after acquiring an additional 138 shares during the last quarter. Finally, Illumine Investment Management LLC grew its position in Neurocrine Biosciences by 1.5% during the first quarter. Illumine Investment Management LLC now owns 9,641 shares of the company’s stock valued at $1,066,000 after acquiring an additional 139 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NBIX. Needham & Company LLC increased their price objective on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Evercore ISI dropped their price objective on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Royal Bank Of Canada dropped their price objective on Neurocrine Biosciences from $146.00 to $144.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Canaccord Genuity Group raised their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, May 6th. Finally, HC Wainwright dropped their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a research note on Tuesday, April 22nd. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $160.90.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the sale, the insider directly owned 18,289 shares of the company’s stock, valued at $2,385,982.94. The trade was a 76.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ingrid Delaet sold 457 shares of Neurocrine Biosciences stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the sale, the insider directly owned 4,730 shares of the company’s stock, valued at $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,251 shares of company stock worth $11,672,602. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $125.01 on Monday. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $154.87. The company has a market cap of $12.40 billion, a PE ratio of 36.99, a price-to-earnings-growth ratio of 0.90 and a beta of 0.25. The stock’s 50 day simple moving average is $128.72 and its 200-day simple moving average is $120.10.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.08. The company had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%. The firm’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.63 earnings per share. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.